EGFR and glioblastoma: In addition, comprehensive molecular profiling has revealed considerable biological heterogeneity within glioblastoma, with markers such as MGMT promoter methylation, TERT promoter mutations, and epidermal growth factor receptor (EGFR) amplification influencing prognosis and treatment response [1,8].